PMID- 38506171
OWN - NLM
STAT- Publisher
LR  - 20240320
IS  - 1468-1293 (Electronic)
IS  - 1464-2662 (Linking)
DP  - 2024 Mar 20
TI  - Sexually transmitted and blood-borne infection risk reduction with methadone and 
      buprenorphine/naloxone among people with prescription-type opioid use disorder: 
      Findings from a Canadian pragmatic randomized trial.
LID - 10.1111/hiv.13636 [doi]
AB  - INTRODUCTION: People who use drugs are disproportionally affected by sexually 
      transmitted and blood-borne infections (STBBIs). While the benefits of methadone 
      in reducing injecting-risk behaviours are well documented, less is known on its 
      impacts on sexual-related risks, as well as its comparative effectiveness to 
      buprenorphine/naloxone, particularly in the context of highly potent opioids. The 
      aim of this study was to estimate the relative effects of buprenorphine/naloxone 
      and methadone on injecting and STBBI risks among people with prescription-type 
      opioid use disorder (POUD). METHODS: Secondary analysis of a pan-Canadian 
      pragmatic 24-week randomized clinical trial comparing methadone and 
      buprenorphine/naloxone models of care among 272 people with POUD (including licit 
      or illicit opioid analgesics, fentanyl). The Risk Behaviour Survey was used to 
      collect injecting and sexual risks at baseline, and weeks 12 and 24. RESULTS: In 
      total, 210 participants initiated treatment (103 buprenorphine/naloxone and 107 
      methadone). At baseline, 113/205 (55.1%) participants reported recently injecting 
      drugs, 37/209 (17.7%) unsafe injection practices and 67/162 (41.4%) high-risk 
      sex. Both methadone and buprenorphine/naloxone were associated with reductions in 
      the prevalence of injection drug use and high-risk sex at weeks 12 and 24 with no 
      interactions between treatment arm and time. CONCLUSION: Methadone and 
      buprenorphine/naloxone were similarly effective in reducing injecting and sexual 
      risk behaviours among people with POUD. CLINICAL TRIALS REGISTRATION: 
      clinicaltrials.gov NCT03033732.
CI  - (c) 2024 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of 
      British HIV Association.
FAU - Socias, M Eugenia
AU  - Socias ME
AUID- ORCID: 0000-0003-2556-7049
AD  - British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
AD  - Department of Medicine, Faculty of Medicine, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Cui, Zishan
AU  - Cui Z
AD  - British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
FAU - Le Foll, Bernard
AU  - Le Foll B
AD  - Translational Addiction Research Laboratory, Campbell Family Mental Health 
      Research Institute and Acute Care Program, Centre for Addiction and Mental 
      Health, Toronto, Ontario, Canada.
AD  - Department of Pharmacology & Toxicology, Medical Sciences Building, University of 
      Toronto, Toronto, Ontario, Canada.
AD  - Department of Family and Community Medicine, Faculty of Medicine, University of 
      Toronto, Toronto, Ontario, Canada.
AD  - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
AD  - Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, 
      Canada.
FAU - Lei, Jingxin
AU  - Lei J
AD  - British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
FAU - Stewart, Sherry
AU  - Stewart S
AD  - Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
AD  - Department of Psychology and Neuroscience, Dalhousie University, Halifax, Nova 
      Scotia, Canada.
FAU - Anand, Rohan
AU  - Anand R
AUID- ORCID: 0000-0002-1957-5336
AD  - British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
AD  - Department of Medicine, Faculty of Medicine, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Jutras-Aswad, Didier
AU  - Jutras-Aswad D
AD  - Research Centre, Centre Hospitalier de l'Universite de Montreal, Montreal, 
      Quebec, Canada.
AD  - Department of Psychiatry and Addictology, Faculty of Medicine, Universite de 
      Montreal, Montreal, Quebec, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT03033732
GR  - SMN-139148/CAPMC/CIHR/Canada
GR  - SMN-139149/CAPMC/CIHR/Canada
GR  - SMN-139150/CAPMC/CIHR/Canada
GR  - SMN-139151/CAPMC/CIHR/Canada
GR  - CIS-144301/CAPMC/CIHR/Canada
GR  - CIS-144302/CAPMC/CIHR/Canada
GR  - CIS-144303/CAPMC/CIHR/Canada
GR  - CIS-144304/CAPMC/CIHR/Canada
PT  - Journal Article
DEP - 20240320
PL  - England
TA  - HIV Med
JT  - HIV medicine
JID - 100897392
SB  - IM
OTO - NOTNLM
OT  - HIV prevention
OT  - buprenorphine
OT  - fentanyl
OT  - medications for opioid use disorder
OT  - methadone
OT  - sexually transmitted and blood-borne infections
EDAT- 2024/03/20 12:42
MHDA- 2024/03/20 12:42
CRDT- 2024/03/20 06:13
PHST- 2023/11/15 00:00 [received]
PHST- 2024/03/06 00:00 [accepted]
PHST- 2024/03/20 12:42 [medline]
PHST- 2024/03/20 12:42 [pubmed]
PHST- 2024/03/20 06:13 [entrez]
AID - 10.1111/hiv.13636 [doi]
PST - aheadofprint
SO  - HIV Med. 2024 Mar 20. doi: 10.1111/hiv.13636.